4-Ethyl-N-hydroxybenzamide | 87828-95-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Ethyl-N-hydroxybenzamide
• CAS: 87828-95-3
• 化学式: C₉H₁₁NO₂
• mdl: MFCD09928942
• 分子量: 165.19
• InChiKey: IEGRWWUXMCFTHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• [EN] NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS POUR INHIBITEURS SÉLECTIFS D'HISTONE DÉSACÉTYLASES ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2014178606A1

  公开（公告）日：2014-11-06

  The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc.

  本发明涉及新型尿素衍生物，更特别地涉及具有组蛋白去乙酰化酶（HDAC）抑制活性的新型尿素衍生物，其异构体，其药学上可接受的盐，它们用于制备包含相同成分的药物的用途，包含相同成分的药物组合物，使用该组合物的治疗方法，以及制备新型尿素衍生物的方法。作为选择性组蛋白去乙酰化酶（HDAC）抑制剂的新型尿素衍生物对于治疗组蛋白去乙酰化酶介导的疾病，如恶性肿瘤、炎症性疾病、类风湿性关节炎、神经退行性疾病等非常有效。
• [EN] NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] NOUVEAUX DÉRIVÉS AZAINDOLE COMME INHIBITEURS SÉLECTIFS DE L'HISTONE DÉSACÉTYLASE (HDAC) ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2015087151A1

  公开（公告）日：2015-06-18

  The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.

  本发明涉及新型的吖吲哚衍生物，特别是具有组蛋白去乙酰化酶（HDAC）抑制活性的新型吖吲哚衍生物，其异构体，药用可接受的盐，水合物或溶剂化物，以及它们用于制备药物组合物的用途，包含同一的药物组合物，使用该药物组合物治疗疾病的方法，以及制备新型吖吲哚衍生物的方法。根据本发明的吖吲哚衍生物是选择性的组蛋白去乙酰化酶（HDAC）抑制剂，可用作治疗恶性肿瘤疾病，炎症性疾病，类风湿性关节炎和神经退行性疾病的治疗剂。
• [EN] TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS<br/>[FR] ACIDES HYDROXAMIQUES SUBSTITUÉS PAR TÉTRAHYDROQUINOLINE EN TANT QU'INHIBITEURS SÉLECTIFS DE L'HISTONE DÉSACÉTYLASE 6
  申请人：UNIV ILLINOIS

  公开号：WO2017142883A1

  公开（公告）日：2017-08-24

  Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.

  组揭示了组蛋白去乙酰化酶抑制剂（HDACIs）及含有其的组合物。还揭示了治疗疾病和病况的方法，其中抑制HDAC能够带来益处，如癌症、神经退行性疾病、神经疾病、创伤性脑损伤、中风、疟疾、自身免疫疾病、自闭症和炎症。
• BRIDGED CARBAMATE MACROLIDES
  申请人：Kim Heejin

  公开号：US20080027012A1

  公开（公告）日：2008-01-31

  The present invention discloses compounds of formulae (I) and (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了式(I)和(II)的化合物或其药学上可接受的盐、酯或前药：这些化合物具有抗菌性能。本发明还涉及含有上述化合物的药物组合物，用于治疗需要抗生素治疗的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。